Current use of phosphodiesterase inhibitors in urology.

@article{Hakky2015CurrentUO,
  title={Current use of phosphodiesterase inhibitors in urology.},
  author={Tariq Said Hakky and Lakshay Jain},
  journal={Turkish journal of urology},
  year={2015},
  volume={41 2},
  pages={88-92}
}
The causes of male erectile dysfunction (ED) are quite variable and are now commonly divided into etiologies such as ischemia, smooth muscle damage, or altered blood flow. Although varying rates of ED have been reported in literature, the number of men with ED is projected to increase worldwide by 2025 to approximately 322 million. Since the introduction of phosphodiesterase 5 (PDE5) inhibitors, there has been a paradigm shift in the treatment of ED because PDE5 inhibitors address a broad… CONTINUE READING